Today, Embla Medical's CEO Sveinn Solvason presented and answered questions about the Q3 2024 results, the expectations for the rest of the year, and details about the increased reimbursement on the US market. Changes that creates a large market potential trough access to more advanced solutions for patients.

Embla Medical will release its Q3 2024 interim report on 22 October 2024. The company’s management will present the results in a virtual live event with a Q&A session the next day, 23 October 2024 at 12:30. Besides the financial results, you can get an update on the recent business and regulatory developments.

Today, Embla Medical's CEO Sveinn Solvason presented the Q2 2024 results, the expectations for the rest of the year, and details about Medicare's finalized proposal that grants access to more advanced solutions for more patients in the US.

Embla Medical will release its Q2 2024 report on 23 July 2024. The company’s management will present the results in a virtual live event with a Q&A session the same day at 13:00. Besides the financial results, you can get an update on recent business- and regulatory developments.

Today, Embla Medical (Össur) CEO Sveinn Solvason presented the results achieved in the first quarter of 2024, and expectations for the rest of the year.

Embla Medical (Össur) will release its Q1 2024 report on 23 April 2024. The company’s management will present the results in a virtual live event with a Q&A session on 24 April 2024 at 14:00. Besides the financial results, you can get an update on recent business developments.

As part of our series Deep Dives, created to give investors a better understanding of the investment case, we together with CEO from Össur (Embla Medical) CEO Sveinn Sölvasson looked at how innovations are a part of their growth strategy, and also looked a little into what the future could bring of product innovations.

We will host a virtual live event with Embla Medical’s CEO Sveinn Sölvasson on 20 March 2024 at 13:00, focusing on how Össur’s innovative solutions and products improve people’s mobility.